1. Home
  2. BAFN vs BIVI Comparison

BAFN vs BIVI Comparison

Compare BAFN & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BAFN
  • BIVI
  • Stock Information
  • Founded
  • BAFN 1999
  • BIVI 2013
  • Country
  • BAFN United States
  • BIVI United States
  • Employees
  • BAFN N/A
  • BIVI N/A
  • Industry
  • BAFN Savings Institutions
  • BIVI Biotechnology: Pharmaceutical Preparations
  • Sector
  • BAFN Finance
  • BIVI Health Care
  • Exchange
  • BAFN Nasdaq
  • BIVI Nasdaq
  • Market Cap
  • BAFN 55.9M
  • BIVI 45.1M
  • IPO Year
  • BAFN N/A
  • BIVI N/A
  • Fundamental
  • Price
  • BAFN $12.98
  • BIVI $3.11
  • Analyst Decision
  • BAFN
  • BIVI Strong Buy
  • Analyst Count
  • BAFN 0
  • BIVI 2
  • Target Price
  • BAFN N/A
  • BIVI $40.00
  • AVG Volume (30 Days)
  • BAFN 8.7K
  • BIVI 3.3M
  • Earning Date
  • BAFN 10-24-2024
  • BIVI 11-13-2024
  • Dividend Yield
  • BAFN 2.37%
  • BIVI N/A
  • EPS Growth
  • BAFN N/A
  • BIVI N/A
  • EPS
  • BAFN 0.73
  • BIVI N/A
  • Revenue
  • BAFN $76,217,000.00
  • BIVI N/A
  • Revenue This Year
  • BAFN N/A
  • BIVI N/A
  • Revenue Next Year
  • BAFN N/A
  • BIVI N/A
  • P/E Ratio
  • BAFN $18.08
  • BIVI N/A
  • Revenue Growth
  • BAFN 7.06
  • BIVI N/A
  • 52 Week Low
  • BAFN $10.15
  • BIVI $1.04
  • 52 Week High
  • BAFN $15.05
  • BIVI $56.54
  • Technical
  • Relative Strength Index (RSI)
  • BAFN 40.68
  • BIVI 56.34
  • Support Level
  • BAFN $13.46
  • BIVI $2.87
  • Resistance Level
  • BAFN $15.05
  • BIVI $3.85
  • Average True Range (ATR)
  • BAFN 0.57
  • BIVI 0.39
  • MACD
  • BAFN -0.05
  • BIVI 0.01
  • Stochastic Oscillator
  • BAFN 32.41
  • BIVI 51.32

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a one bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: